What are the most common supply chain visibility challenges after an acquisition in pharmaceuticals’ medical devices?

Post-acquisition, supply chains rarely merge cleanly. Different ERP systems, vendor contracts, and compliance standards collide. Often, the acquiring firm’s supply chain operates in SAP, while the target uses Oracle or a niche pharma-specific platform. This fragmentation means visibility is spotty at best.

For mid-level HR, this creates challenges beyond technology. Cultural misalignment among procurement, quality, and distribution teams delays data sharing. Silos deepen as people protect their legacy processes. A 2023 Deloitte report found 58% of pharma mergers fail to consolidate supply chain data within 12 months, directly hurting operational efficiency.

How does culture impact supply chain visibility integration post-acquisition?

Culture often gets overlooked but it’s pivotal. Medical device firms in pharma emphasize regulatory compliance and risk mitigation. If teams from both sides have different attitudes toward transparency or data ownership, integration stalls.

One example: after a 2022 acquisition, a US-based medical device unit resisted sharing supplier quality incident data with the European parent. The root was trust, not technology. HR-led workshops using tools like Zigpoll revealed employees feared blame or job loss tied to data transparency.

Addressing culture requires more than messaging. It takes ongoing pulse surveys, cross-functional training, and visible leadership commitment to transparency. Otherwise, data remains siloed in parallel systems.

How do connected product strategies influence supply chain visibility in this context?

Connected product strategies—embedding IoT and sensors in medical devices—add layers to supply chain visibility. They generate real-time usage, location, and condition data across distribution networks.

Post-acquisition, integrating these data streams exposes gaps in tracking and forecasting. For example, wearables with cloud connectivity require continuous uptime monitoring. If visibility systems don’t talk, the combined company risks stockouts or delayed recalls.

A 2024 Pharma Insight survey showed 42% of firms with connected devices struggled to consolidate device telemetry data post-merger. Mid-level HR can champion interdisciplinary coordination between supply chain, IT, and R&D to ensure data from connected products informs inventory and supplier decisions.

What specific tech stack challenges arise with supply chain visibility after pharma M&A?

Often, the problem is overlapping tools that don’t integrate. One medical device client post-acquisition had teams using three different LIMS (Laboratory Information Management Systems), each with different supplier quality modules. This fragmentation made consolidated reporting nearly impossible.

HR can play a role by encouraging cross-departmental audits of existing tech platforms and identifying redundancies. Prioritize tools with pharma-specific compliance features—such as CFR 21 Part 11 electronic records capabilities.

Keep in mind: migrating to a single system is time-intensive and costly. Interim solutions like middleware or API integrations can plug visibility gaps but introduce complexity and require ongoing governance.

How can mid-level HR professionals support culture and technology alignment for visibility improvement?

HR can convene cross-functional joint task forces focused on supply chain transparency. Include procurement, quality assurance, IT, and connected device R&D. Use survey tools like Zigpoll or Culture Amp to gather feedback on pain points and communication barriers.

Encourage transparency by framing visibility as a collective risk mitigation effort, not a policing mechanism. Reward teams that share data and collaborate across legacy boundaries.

Also, embed change management methods tailored for pharma’s regulatory environment. For example, tailor training materials to address compliance in supplier management and connected device data handling.

Are there early wins HR can help realize to demonstrate supply chain visibility progress?

Yes. Start with supplier scorecards that combine quality, delivery timeliness, and risk metrics from both legacy companies. One medical device firm boosted supplier compliance from 82% to 91% within six months of acquisition by standardizing reporting templates across teams.

Another tactic is improving recall traceability via connected product data. Post-merger, a company consolidated their IoT device tracking with supply chain systems, cutting recall response times by 30%.

These wins build momentum. The downside: they require persistent alignment and often bring resistance from teams protective of their data silos.

What should HR avoid when tackling supply chain visibility post-acquisition?

Avoid pushing technology solutions without addressing culture first. Too many firms buy sophisticated dashboards but find no one trusts or uses the data.

Also, resist assuming all data can be consolidated quickly. Pharma supply chains are complex, involving contract manufacturers, wholesalers, and regulatory bodies. Sometimes dual systems must run in parallel for years.

Lastly, don’t overlook the people side. If teams feel visibility initiatives threaten their roles or autonomy, engagement drops and errors rise.

How can HR integrate survey and feedback tools effectively in this process?

Deploy pulse surveys early and often, targeting supply chain and connected product teams. Zigpoll offers pharma-specific templates for assessing collaboration and transparency barriers.

Combine qualitative feedback with quantitative KPIs, such as system uptime, supplier data completeness, and recall cycle times.

Use surveys to track progress on culture change initiatives and identify pockets of resistance or misunderstanding. Then, tailor communication and training accordingly.

What final actions should mid-level HR prioritize in supply chain visibility integration post-M&A?

First, map existing supply chain and connected product data flows from both companies. Identify critical gaps in visibility.

Second, coordinate cross-functional teams to align around common goals like regulatory compliance, supplier risk reduction, and recall efficiency.

Third, champion culture change by using surveys and workshops to build trust and transparency habits.

Fourth, recommend pragmatic technology integrations that balance short-term visibility gains with long-term platform consolidation.

This approach reduces post-acquisition supply chain disruption and supports the medical device business’s compliance and patient safety priorities.